|Bid||11.00 x 1400|
|Ask||11.40 x 1400|
|Day's Range||10.80 - 11.32|
|52 Week Range||10.45 - 22.91|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Mental illnesses are tough to treat, and researchers are always looking for better ways to pull through for patients. In this vein, novel interventions based on the illicit psychedelic drugs of yesteryear could well become the advanced mental health therapies of tomorrow. Right now, there's a rapidly growing field of biotech companies developing treatments with psychedelics, and there's money to be made for investors who can identify the future winners.
In any sector with entrenched competitors, there's room for a disruptive upstart to come in and steal oodles of market share. Before patients even get to the front door of the therapy clinic, they've interacted with the company's automated online prep platform, which helps them to get ready for their experience.
Ronan Levy, Field Trip Health Chairman, joins Yahoo Finance to discuss the psychedelic company’s debut on the Nasdaq and the development of the psychedelics.